


Initial results from a Phase II study (TACTI-002) of efitlagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer (HNSCC) patients

Authors: Forster M¹; Felip E²; Doger B³; Pousa P⁴; Carcereny E⁵; Bajaj P⁶; Church M⁷; Peguero J⁸; Roxburgh P⁹; Triebel F¹⁰

- Affiliates:**
1. Forster: UCL Cancer Institute / University College London Hospitals NHS Foundation, London, UK
 2. Felip: Vall d'Hebron University Hospital, Barcelona, Spain
 3. Doger: START Madrid- Fundación Jiménez Díaz, Madrid, Spain
 4. Lopez Pousa: Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
 5. Carcereny: Catalan Institute of Oncology Badalona-Hospital Germans Trias i Pujol, B-ARGO group; Badalona, Spain
 6. Bajaj: Griffith University, Gold Coast, Australia
 7. Church: The Christie NHS Foundation Trust, Manchester, UK
 8. Peguero: Oncology Consultants, P.A., Houston, USA
 9. Roxburgh: University of Glasgow/ Beatson West of Scotland Cancer Centre, Glasgow, UK
 10. Triebel: Research & Development, Immunetep S.A.S., Orsay, France

Background



Efitlagimod alpha (efti; previously IMP321) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules, to mediate antigen presenting cells (APC) and then activation of CD8 T-cells.

Efti is a first-in-class APC activator.

The rationale for combining efti and pembrolizumab comes from their complementary mechanisms of action. Efti activates APCs, leading to an increase in activated T cells, modulating the tumor micro-environment and potentially increasing the likelihood of responding to pembrolizumab.

Combining an APC activator such as efti to pembrolizumab is therefore fundamentally different from many other trials combining two checkpoint inhibitors such as an anti-LAG-3 mAb with an anti-PD-1 mAb.

Previous clinical trial experience with the combination of efti and pembrolizumab in patients with metastatic melanoma (TACTI-mel; NCT02676869) demonstrated the combination to be safe and showed encouraging signs of efficacy.

We hereby report results from stage 1 part C of a phase II umbrella trial (TACTI-002, NCT03625323).



Copies of this e-poster obtained through QR and/or text key codes are for personal use only and may not be reproduced without written permission of the authors.

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA provided pembrolizumab for the study. The trial identifiers are IMP321-PD15 (Sponsor code), Keynote-PN798 (MSD code), 2018-001994-25 (EudraCT) and NCT03625323 (ClinicalTrials.gov). Corresponding author: Frederic Triebel, frederic.triebel@immunetep.com

First Author COI: Martin Forster
 Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck Sharp & Dohme; Nanobiotix; Novartis; Oxford VacMedix; Pfizer; PharmaMar; Roche; Takeda
 Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD Oncology (Inst)
 Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Celgene; Guardant Health; MSD Oncology; Roche

APC...antigen-presenting cell
 AE...adverse event
 BOR...best overall response
 DCR...disease control rate
 DMC...Data Monitoring Committee
 ECOG...Eastern Cooperative Oncology Group
 HNSCC...head and neck squamous cell cancer
 ICI...immune checkpoint inhibitor
 iRECIST...Immune Response Evaluation Criteria In Solid Tumors

LAG-3...Lymphocyte Activation gene-3
 MHC...Major Histocompatibility Complex
 NSCLC...non-small cell lung cancer
 PD-L1, PD-L2...Programmed Death ligand-1, -2
 PD-X...PD-1 or PD-L1 targeted therapy
 PFS...progression-free survival
 ORR...objective response rate
 SAE...serious adverse event
 TEAE...treatment-emergent adverse event

Trial Design

Part A: 1st line, PD-X naïve NSCLC; Stage IIIB not amenable to curative treatment or stage IV not amenable to EGFR/ALK based therapy, treatment-naïve for advanced/metastatic disease

Part B: 2nd line, PD-X refractory NSCLC; Pts after failure of 1st line therapy for metastatic disease which incl. at least 2 cycles of PD-X

Part C: 2nd line PD-X naïve HNSCC; Recurrent disease not amenable to curative treatment, or metastatic disease incurable by local therapies after failure of prior platinum-based therapy

General Features/Objectives:


- Primary Endpoint: Objective Response Rate (iORR), as per iRECIST
- Secondary Endpoints: progression free survival (PFS) and overall survival (OS)
- Central assessment of tumor cell PD-L1 expression after enrolment
- Blood samples for PK/PD assessments and anti-drug antibody evaluation are collected

The study has a Simon's two-stage design:

N1 patients are recruited into the first stage. Additional patients (N2) will be recruited for each part if the pre-specified threshold for ORR is met. In total, 109 patients are planned to be enrolled.

Indication	Threshold r1	Initial no. of pts (N1)	Add. no. of pts (N2)	N total
Part A: NSCLC 1 st line	4	17	19	36
Part B: NSCLC 2 nd line	1	23	13	36
Part C: HNSCC 2 nd line	2	18	19	37

Efti is administered as 30 mg subcutaneous injection every 2 weeks for the first 8 cycles and every 3 weeks for the following 9 cycles. Pembrolizumab is administered at a standard dose of 200 mg intravenous infusion every 3 weeks for maximum of 2 years.



Legend: 1 cycle = 3 weeks; q2w – every 2 weeks, q3w every 3 weeks

Enrolment to Part A + C stage 1 was completed in 2019, while Part B stage 1 and Part A stage 2 were completed in 2020. Recruitment in Part C stage 2 is ongoing.

Exposure and Safety¹

Summary - Exposure:

- In total, 88 pts were enrolled in all three parts and stages until data cut-off¹.
- Pts received median 5.5 (range 1-22) efti injections and median of 4 (range 1-25) pembrolizumab infusions

Overview - Safety:

- No treatment-related death
- 3 treatment-related adverse events leading to permanent discontinuation of efti treatment (drug-induced hepatitis G4; ALT & AST elevation G3; diarrhea G1)
- No new safety signals of this new combination identified until cut-off

Further safety data can be found on poster 1266P:



^{1,2} - Data cut-off date: 21st Aug 2020

Part C stage 1 – PD-X naïve 2nd line HNSCC², PD-L1 all comer

- 18 patients enrolled, treated and evaluated (16 with ≥ 1 post baseline scan)
- Different types of HNSCC:
 - Oropharynx n=6; 33.3 %
 - Hypopharynx n=5; 27.8 %
 - Oral cavity n=5; 27.8 %
 - Larynx n=2; 11.1 %

Tumor response - iBOR as per iRECIST	N (%) Total (N=18)
Complete Response (iCR)	2 (11.1)
Partial Response (iPR)	5 (27.8)
Stable Disease (iSD)	2 (11.1)
Progressive Disease (iUPD/iCPD)	7 (38.9)
Not Evaluable*	2 (11.1)
Objective Response Rate (iORR) [95 % CI interval]	7 (38.9) [17.3 – 64.3]
Disease Control Rate (iDCR)	9 (50.0 %)

* - pt dropped out prior to first re-staging

Summary:



- iORR of 38.9 % [95 % CI 17.3%, 64.3%]
- 11.1 % (2 pts) with complete response
- 6 of 7 responses confirmed
- 1 response at CPS of 2 %
- 1 response after pseudo-progression
- 6 of 7 responders continue therapy at 6+ months → median duration of response not reached
- Median PFS is 4.26 months [95 % CI 1.48; NE]
- 47.1 % and 39.2 % of patients are progression-free at 6 and 9 months, respectively
- 66.7 % of patients alive at 6 and 9 months with a minimum follow-up of 8+ months → median not yet reached

Baseline Parameters (n=18)	N (%)
Age [yrs]	Median 66 (48-78)
Female / Male	1 (5.6) / 17 (94.4)
ECOG 0 / 1	10 (55.6) / 8 (44.4)
Current / Ex-smokers	17 (94.4)
Previous chemotherapy	18 (100 %)
Previous cetuximab	9 (50 %)

- Patients with all different PD-L1 subgroups (by CPS) enrolled → PD-L1 all comer trial

PD-L1 distribution*	N (%)	Historically expected**	Pts with iPR/iCR
CPS < 1 %	3 (16.7 %)	15 %	0
CPS 1-19 %	5 (27.8 %)	45 %	1
CPS ≥ 20 %	7 (38.9 %)	40 %	6
NE	3 (16.7%)		0

* Centrally assessed by Dako PD-L1 IHC 22C3 pharmDx
 ** - Burtness et al (2019); [https://doi.org/10.1016/S0140-6736\(19\)32591-7](https://doi.org/10.1016/S0140-6736(19)32591-7)



Conclusion

HNSCC

- iORR of 38.9 % in PD-L1 all comer 2nd line HNSCC, including 2 complete responses → encouraging if referenced to pembrolizumab alone in comparable patient population (KN-040)
- Response seen in < 20 % PD-L1 CPS group
- Median PFS of 4.26 months and durability of responses are encouraging

Overall

- Combination of efti and pembrolizumab in NSCLC and HNSCC patients is safe and well-tolerated
- Results underlining the potential synergy of the APC activator efti with the checkpoint inhibitor pembrolizumab may result in synergistic therapeutic activity with an excellent safety profile
- Data from the NSCLC part A stage 1 is presented on poster 1266P